Michael Gibertini
Keine laufenden Positionen mehr
Profil
Michael Gibertini served as the Chief Operating Officer at INC Research Holdings, Inc. from 2016 to 2017.
He then worked as the President-Clinical Development at Syneos Health, Inc. from 2017 to 2018.
Gibertini holds a doctorate degree from the University of Houston.
Ehemalige bekannte Positionen von Michael Gibertini
Unternehmen | Position | Ende |
---|---|---|
SYNEOS HEALTH, INC. | Corporate Officer/Principal | 01.08.2018 |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | Geschäftsführer | 13.11.2017 |
Ausbildung von Michael Gibertini
University of Houston | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | Commercial Services |
Syneos Health, Inc.
Syneos Health, Inc. BiotechnologyHealth Technology Syneos Health, Inc. engages in the provision of biopharmaceutical solutions. It operates through the Clinical Solutions and Commercial Solutions segments. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. It also offers individual services including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, and consultancy services. The company was founded in 1998 and is headquartered in Morrisville, NC. | Health Technology |